Valuation: Jazz Pharmaceuticals plc

Market Cap 13.53B 12.06B 11.17B 10.16B 19.06B 1,283B 19.38B 134B 52.69B 670B 50.76B 49.7B 2,143B P/E 2026 *
16.1x
P/E 2027 * 12.7x
Enterprise Value 15.58B 13.88B 12.86B 11.69B 21.94B 1,477B 22.3B 154B 60.66B 772B 58.44B 57.22B 2,467B EV / Sales 2026 *
3.3x
EV / Sales 2027 * 2.7x
Free-Float
96.83%
Yield 2026 *
-
Yield 2027 * -
1 day-0.86%
1 week-3.84%
Current month-9.97%
1 month-13.42%
3 months-15.80%
6 months+2.46%
Current year+22.61%
1 week 206.71
Extreme 206.71
217.57
1 month 206.71
Extreme 206.71
244.48
Current year 156.95
Extreme 156.95
266.38
1 year 128.8
Extreme 128.8
266.38
3 years 95.49
Extreme 95.49
266.38
5 years 95.49
Extreme 95.49
266.38
10 years 86.88
Extreme 86.88
266.38
Manager TitleAgeSince
Chief Executive Officer 54 2025-08-10
Director of Finance/CFO 62 2024-02-29
Chief Tech/Sci/R&D Officer 54 2023-07-31
Director TitleAgeSince
Chairman 62 2003-02-28
Director/Board Member 65 2012-01-17
Director/Board Member 66 2009-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
10/6/26 Sell

Chief Executive Officer

-2,000 0.0031%
10/1/26 Sell

Founder

-6,000 0.0092%
9/10/26 Sell

General Counsel

-1,200 0.0018%
Change 5-day change 1-year change 3-year change Capi.($)
-0.86%-3.84%+53.19%+57.87% 13.65B
-1.33%+4.88%+54.50%+109.94% 1,120B
-0.69%-3.77%+31.35%+66.62% 616B
-0.96%+0.55%+23.13%+94.26% 504B
+0.24%+5.58%+33.98%+59.40% 367B
-1.59%-1.25%+69.39%+43.02% 360B
-0.40%+3.53%+19.17%+46.55% 288B
-0.37%+3.11%-1.26%+18.23% 258B
-1.75%+1.76%+42.21%+51.44% 234B
-2.00%+1.75%+24.64%+95.14% 194B
Average -0.97%+1.69%+35.03%+64.25% 395.45B
Weighted average by Cap. -0.99%+2.40%+37.95%+75.46%

Financials

2026 *2027 *
Net sales 4.72B 4.21B 3.9B 3.55B 6.65B 448B 6.76B 46.78B 18.4B 234B 17.72B 17.35B 748B 4.99B 4.45B 4.12B 3.75B 7.04B 474B 7.15B 49.47B 19.45B 247B 18.74B 18.35B 791B
Net income 831M 741M 686M 624M 1.17B 78.81B 1.19B 8.23B 3.24B 41.19B 3.12B 3.05B 132B 1.14B 1.02B 942M 857M 1.61B 108B 1.63B 11.3B 4.44B 56.54B 4.28B 4.19B 181B
Net Debt 2.05B 1.82B 1.69B 1.54B 2.88B 194B 2.93B 20.26B 7.97B 101B 7.67B 7.51B 324B -25.09M -22.36M -20.71M -18.83M -35.34M -2.38B -35.92M -248M -97.7M -1.24B -94.12M -92.15M -3.97B
Projected Income Statement - Annual - Jazz Pharmaceuticals plc
Logo Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, ABS-1230, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
Employees
2,890
Date Price Change Volume
26-10-19 US$208.43 -0.86% 716,945
26-10-16 US$210.23 -1.95% 636,712
26-10-15 US$214.42 +2.28% 886,417
26-10-14 US$209.65 -0.35% 891,560
26-10-13 US$210.39 -2.93% 812,641
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - Jazz Pharmaceuticals plc
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
208.43USD
Average target price
294.64USD
Spread / Average Target
+41.36%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Jazz Pharmaceuticals plc
  1. Stock Market
  2. Stocks
  3. JAZZ Stock